

# Cardiology RESEARCH REVIEW™

Making Education Easy

Issue 107 – 2023

## In this issue:

- Benefits of CRT differ according to QRS characteristics
- Intravascular imaging-guided vs angiography-guided complex PCI
- Transcatheter repair of tricuspid regurgitation
- Routine invasive vs conservative strategy in frail older adults with NSTEMI
- Influenza vaccination as prevention therapy for patients with stable coronary artery disease
- Artificial intelligence vs sonographer assessment of cardiac function
- Up-titration of guideline-directed medical therapies for acute HF in elderly patients
- Five-year follow-up after transcatheter repair of secondary mitral regurgitation
- Family screening for bicuspid aortic valve and aortic dilatation
- Remote haemodynamic monitoring of pulmonary artery pressure in HF patients

### Abbreviations used in this issue

**ACS** = acute coronary syndrome  
**CRT** = cardiac resynchronisation therapy  
**HF** = heart failure  
**HR** = hazard ratio  
**LVEF** = left ventricular ejection fraction  
**MI** = myocardial infarction  
**NSTEMI** = non-ST-segment elevation MI  
**PCI** = percutaneous coronary intervention  
**TEER** = transcatheter edge-to-edge repair  
**WHO** = World Health Organization

Kindly Supported by



**Hauora  
Taiwhenua**  
Rural Health  
Network

## Welcome to the latest issue of Cardiology Research Review.

In this issue, a meta-analysis confirms that CRT improves outcomes in patients with intraventricular conduction delay but not right bundle branch block, the TRILUMINATE Pivotal trial reports encouraging results for percutaneous tricuspid TEER in patients with severe tricuspid regurgitation, and Spanish investigators show why a policy of medical management and watchful observation is recommended for older patients with frailty and NSTEMI. Also in this issue, a meta-analysis suggests that we should recommend flu vaccinations to patients with coronary artery disease, and US investigators look at the utility of artificial intelligence for the assessment of cardiac function.

I hope you find these and the other selected articles interesting and look forward to receiving any feedback you may have.

Kind regards,

**Professor Alexander Sasse**

[alexandersasse@researchreview.co.nz](mailto:alexandersasse@researchreview.co.nz)

## Cardiac resynchronization therapy improves outcomes in patients with intraventricular conduction delay but not right bundle branch block

**Authors:** Friedman DJ et al.

**Summary:** This meta-analysis of randomised controlled trials investigated the benefits of CRT in patients with differing QRS characteristics. Patient-level data from the pivotal CRT trials (MIRACLE, MIRACLE-ICD, MIRACLE-ICD II, REVERSE, RAFT, BLOCK-HF, COMPANION, and MADIT-CRT) were analysed using Bayesian Hierarchical Weibull survival regression models to assess CRT benefit by QRS morphology and duration. Patients had left bundle branch block (LBBB; n=4549), right bundle branch block (RBBB; n=691), and intraventricular conduction delay (IVCD; n=1024). Overall, 61% of patients received CRT with or without an implantable cardioverter defibrillator. Meta-analysis of the data showed that CRT was associated with a lower risk of HF hospitalisation or death overall (HR 0.73, credible interval [CrI] 0.65–0.84), and in subgroups of patients with QRS  $\geq$ 150ms and either LBBB (HR 0.56, CrI 0.48–0.66) or IVCD (HR 0.59, CrI 0.39–0.89), but not RBBB (HR 0.97, CrI 0.68–1.34). No significant association of CRT with HF hospitalisation or death was observed when QRS was <150ms, regardless of QRS morphology.

**Comment:** This meta-analysis of CRT trials has a very clear message. It included 6264 patients and looked mainly at QRS duration and BBB morphology. Outcome was HF hospitalisation or mortality. Patients with a QRS <150ms or RBBB did not demonstrate a benefit in the measured end-points from CRT. On the other hand, LBBB with QRS >150ms (HR 0.56) and IVCD (HR 0.59) benefited from CRT. Nothing really new, but a confirmation.

**Reference:** *Circulation* 2023;147(10):812-23

[Abstract](#)

## Intravascular imaging-guided or angiography-guided complex PCI

**Authors:** Lee JM et al., for the RENOVATE-COMPLEX-PCI Investigators

**Summary:** This multicentre, open-label trial in South Korea compared clinical outcomes after intravascular imaging-guided versus angiography-guided PCI for complex coronary artery lesions. 1639 patients with complex coronary artery lesions were randomised 2:1 to undergo either intravascular imaging-guided or angiography-guided PCI; the primary end-point was a composite of death from cardiac causes, target vessel-related MI, or clinically driven target vessel revascularisation. During a median follow-up of 2.1 years, a primary end-point event occurred in 76 patients in the intravascular imaging group and 60 patients in the angiography group (HR 0.64, 95% CI 0.45–0.89; p=0.008). Procedure-related safety events did not differ significantly between groups.

**Comment:** This is quite a topic especially between cardiologists of different generations ... for which patients is PCI with intravascular imaging relevant? Being mindful of longer procedures (here 16.5 min) and current waiting times. This trial implanted specifically biodegradable or biocompatible polymer-coated everolimus-eluting stents in complex lesions. Target vessel failure was less common in patients with imaging-guided PCI (cumulative incidence at 3 years, 7.7% vs 12.3%; p=0.008), as was cardiovascular death (HR 0.47, 95% CI 0.24–0.93). Ostial, left main stem and chronic total occlusion lesions benefited in particular from intracoronary imaging.

**Reference:** *N Engl J Med* 2023;388(18):1668-79

[Abstract](#)

[CLICK HERE](#) to read previous issues of Cardiology Research Review

**Jardiance®**  
(empagliflozin)

**FULLY FUNDED**  
with Special Authority criteria\*  
for the treatment of T2D

**For your patients with type 2 diabetes<sup>†</sup>**

**THE POWER TO ACCOMPLISH MORE**  
Above and beyond glycaemic control<sup>†,2</sup>

Not an actual patient.

## Transcatheter repair for patients with tricuspid regurgitation

**Authors:** Sorajja P et al., for the TRILUMINATE Pivotal Investigators

**Summary:** This randomised controlled trial investigated the use of percutaneous tricuspid TEER for severe tricuspid regurgitation. 350 patients (mean 78 years, 54.9% female) with symptomatic severe tricuspid regurgitation were enrolled at 65 centres in the US, Canada, and Europe and were randomised 1:1 to receive either TEER or medical therapy (controls). The primary end-point was a hierarchical composite that included death from any cause or tricuspid valve surgery, hospitalisation for HF, and an improvement in quality of life measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). During the 1-year follow-up, the incidence of death or tricuspid valve surgery and the rate of HF hospitalisations did not differ significantly between groups, but quality of life improved significantly in the TEER group compared with controls ( $p < 0.001$ ).

**Comment:** A clip to treat tricuspid regurgitation (actually usually two); TEER for the tricuspid valve. 350 patients with functional severe symptomatic tricuspid regurgitation were randomised to control vs TEER. Conventional surgery is often not very promising in these patients. The enrolled patients had comparatively moderate symptoms before the study and the main outcome was a quality of life assessment. The procedure is technically demanding and 87% had a significant reduction in tricuspid regurgitation. Correlating with the degree of tricuspid regurgitation reduction was an increase in the quality of life parameter driving the positive outcome of the study. However, hospitalisation and mortality were not different. It appears that the optimal patient group benefiting from this procedure has not yet been identified, but the results are encouraging.

**Reference:** *N Engl J Med* 2023;388(20):1833-42

[Abstract](#)

<sup>†</sup>38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62;  $p < 0.001$ ).<sup>2</sup> \*JARDIANCE is a funded medicine. Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. Jardiance is fully funded for the treatment of T2DM. Jardiance is not funded for the treatment of heart failure with reduced ejection fraction. <sup>†</sup>In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. <sup>2</sup>The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE<sup>®</sup> ( $p < 0.001$ ).<sup>1,2</sup> 1.JARDIANCE<sup>®</sup> Data Sheet 2021 2.Zinman B et al. *N Engl J Med.* 2015;373(22):2117-2128

**JARDIANCE<sup>®</sup> empagliflozin 10mg, 25mg film coated tablets.** Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp> **INDICATION:** Type 2 diabetes mellitus - Glycaemic control: Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: Monotherapy - When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; Add-on combination therapy - With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. **Prevention of cardiovascular (CV) events:** In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, Jardiance should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **Heart failure:** In adult patients with heart failure (NYHA class II-IV) and reduced ejection fraction, with or without type 2 diabetes mellitus: to reduce the risk of hospitalisation for heart failure; to slow kidney function decline. **DOSAGE AND ADMINISTRATION:** Type 2 diabetes mellitus: Recommended starting dose is 10mg once daily. Patients with type 2 diabetes mellitus tolerating 10mg once daily and requiring additional glycaemic control, increase dose to 25mg once daily. **Heart failure:** Recommended dose is 10mg once daily. Can be taken with or without food. No dose adjustment is recommended based on age, patients with eGFR  $\geq 30$  mL/min/1.73m<sup>2</sup> (T2DM) or  $\geq 20$  mL/min/1.73m<sup>2</sup> (HF), or hepatic impairment. When Jardiance is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with severe renal impairment (T2DM: eGFR  $< 30$  mL/min/1.73m<sup>2</sup>). **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); contraindicated when eGFR  $< 30$  mL/min/1.73m<sup>2</sup> (T2DM); not recommended when eGFR  $< 20$  mL/min/1.73m<sup>2</sup> (HF); assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged  $\geq 75$  years); complicated urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children ( $< 18$  years). **INTERACTIONS:** Diuretics; insulin and SU; interference with 15-nhydroglucitol assay. **ADVERSE REACTIONS:** Very common: hypoglycaemia (when used with metformin in combination with SU or insulin - patients with T2DM); volume depletion (patients with HF). Common: hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin - patients with T2DM); hypoglycaemia (patients with HF); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus (patients with T2DM); allergic skin reactions (e.g. rash, urticaria); increased urination (patients with T2DM); thirst (patients with T2DM); serum lipids increased; volume depletion (patients aged  $\geq 75$  years); constipation. For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption. Through inhibition of SGLT2, excessive glucose is excreted in the urine. Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, increasing tubuloglomerular feedback and reducing intraglomerular pressure, lowering both pre- and afterload of the heart, and downregulating sympathetic activity. **PRESCRIPTION MEDICINE - JARDIANCE is a funded medicine - Restrictions apply: Pharmaceutical Schedule, Special Authority.** Jardiance is fully funded for the treatment of T2DM. Jardiance is not funded for the treatment of heart failure with reduced ejection fraction. JARDIANCE<sup>®</sup> is a registered trademark of Boehringer Ingelheim. BOEHRINGER INGELHEIM (N.Z.) Ltd. Level 3, 2 Osterley Way, Manukau, Auckland 2104. TAPS MR8157/PC-NZ-100168 April 2022 BOE000418

**Boehringer Ingelheim**  
Boehringer Ingelheim (NZ) Ltd.  
PO Box 76216 Manukau City,  
Auckland 2241. Phone 0800 802 461

**Lilly**  
Eli Lilly and Company (NZ) Ltd.  
PO Box 109197 Newmarket,  
Auckland 1149. Phone 0800 500 056  
NZBN 9429039560643

### RACP MyCPD Program participants

can claim the time spent reading and evaluating research reviews as CPD in the online MyCPD program.

Please contact [MyCPD@raccp.edu.au](mailto:MyCPD@raccp.edu.au) for any assistance.

South Link Education Trust | **South GPCME**  
General Practice Conference & Medical Exhibition

10-13 AUGUST 2023  
TE PAE CHRISTCHURCH CONVENTION CENTRE  
[gpccme.co.nz](http://gpccme.co.nz)

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)



## Effect of routine invasive vs conservative strategy in older adults with frailty and non-ST-segment elevation acute myocardial infarction

**Authors:** Sanchis J et al.

**Summary:** This Spanish trial compared 1-year outcomes after invasive versus conservative treatment strategies in frail, older patients with NSTEMI. 167 older adults ( $\geq 70$  years) with frailty (Clinical Frailty Scale score  $\geq 4$ ) and NSTEMI were randomised to routine invasive (coronary angiography and revascularisation if feasible) or conservative (medical treatment with coronary angiography for recurrent ischaemia) strategies at 13 Spanish hospitals in 2017–2021. The primary end-point was the number of days alive and out of the hospital (DAOH) from discharge to 1 year. Mean DAOH did not differ significantly between groups, but was slightly longer with conservative versus invasive management (312 vs 284 days;  $p=ns$ ).

**Comment:** A recurrent theme – how to manage older patients with NSTEMI, in this trial with an emphasis on frailty. Patients over 70 years with NSTEMI were randomised and prospectively included, they had to have 4 or more points on the Clinical Frailty Scale. End-point was ‘days alive out of hospital’ after 1 year; 167 patients were enrolled and the trial was stopped early. While DAOH was 28 days shorter for invasive management, overall there was no significant difference ( $p=0.12$ ). There was also no difference regarding cardiac death, reinfarction and revascularisation ( $p=0.78$ ). Check out the frailty score used – ‘4’ refers to ‘vulnerable’. Invasive management in this group of patients would have to be considered with caution.

**Reference:** *JAMA Intern Med* 2023;183(5):407-15

[Abstract](#)

## Influenza vaccination as prevention therapy for stable coronary artery disease and acute coronary syndrome

**Authors:** Barbeta LMDS et al.

**Summary:** This meta-analysis investigated the effectiveness of influenza vaccination in patients with ACS and stable coronary artery disease. A search of Cochrane Controlled Register of Trials (CENTRAL), Embase, MEDLINE, www.Clinicaltrials.gov, and the WHO International Clinical Trials Registry Platform from inception to Sep 2021 identified five randomised controlled trials ( $n=4187$ ) that were suitable for inclusion. Meta-analysis of the data showed that influenza vaccination significantly reduced the risk of all-cause mortality (relative risk [RR] 0.56, 95% CI 0.38–0.84), cardiovascular mortality (RR 0.54, 95% CI 0.37–0.80), major acute cardiovascular events (RR 0.66, 95% CI 0.49–0.88), and ACS (RR 0.63, 95% CI 0.44–0.89), but not the risk of revascularisation, stroke or transient ischaemic attack, or hospitalisation for HF.

**Comment:** Should you recommend flu vaccinations to patients with coronary artery disease? Here a meta-analysis compared data from 4187 patients in five randomised controlled trials. Across trials, 61–81.4% were men, mean age was around 60. Outcomes showed a reduction in mortality by 44%. Cardiovascular events were reduced by 34%. These effects were mostly seen in patients with previous ACS, not in stable coronary artery disease. Influenza vaccination was shown to be safe 72h after an ACS, and the authors discuss vaccinating ACS patients pre-discharge as a standard procedure.

**Reference:** *Am J Med* 2023;136(5):466-75

[Abstract](#)

## Blinded, randomized trial of sonographer versus AI cardiac function assessment

**Authors:** He B et al.

**Summary:** This blinded, non-inferiority clinical trial compared the accuracy of a cardiac sonographer with that of artificial intelligence (AI) for the assessment of LVEF. 3495 transthoracic echocardiograms were randomised 1:1 to be evaluated by AI or one of 25 cardiac sonographers (mean 14.1 years’ practise). The echocardiograms were then assessed by one of ten cardiologists (mean 12.7 years’ practise). The primary outcome was the change in LVEF between initial AI or sonographer assessment and final cardiologist assessment, defined as the proportion of echocardiograms with substantial ( $>5\%$ ) change. Substantial change between the initial and final assessments occurred in 16.8% of studies in the AI group and 27.2% in the sonographer group (between-group difference,  $-10.4\%$ ;  $p<0.001$  for non-inferiority).

**Comment:** AI is everywhere. How well does AI compare to sonographers in the assessment of LV function? Controversial for some – I know – the final and reference assessment of LV function was done by cardiologists. 1740 AI studies, 1755 sonographer studies. Blinded and randomised. Outcome was ‘substantial change’ between initial and final assessment, occurring in 16.8% of the AI and 27.2% of sonographer assessments ( $p<0.001$ ). Ok, this is a ‘Nature’ paper. But two-thirds of studies derived LVEF from one plane only. And cardiologists frequently guessed assessment and unblinded the study. And a comparison with a different imaging method for LVEF would make more sense. But I guess it showed that the AI algorithm they used can work.

**Reference:** *Nature* 2023;616:520-4

[Abstract](#)

## Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients

**Authors:** Arrigo M et al.

**Summary:** This subanalysis of the STRONG-HF trial investigated the safety and efficacy of up-titration of guideline-directed medical therapy (GDMT) for acute HF in older patients ( $>65$  years). Patients hospitalised with acute HF who were not receiving optimal GDMT were randomised to high-intensity care (HIC; rapid up-titration of GDMT and close follow-up) or usual care. The effect of HIC on the primary end-point (180-day death or readmission for HF) was numerically higher in younger patients (adjusted HR [aHR] 0.51, 95% CI 0.32–0.82) than older patients (aHR 0.73, 95% CI 0.46–1.15), but did not differ significantly between age-groups after adjustment for COVID-related deaths. HIC induced larger improvements in quality of life to day 90 in younger patients ( $p=0.032$ ), but was associated with similar rates of adverse events in each age group.

**Comment:** How fast should we get HF patients to the recommended dose of drugs? Rapid up-titration of HF medication – essentially giving the full dose within 2 weeks (HIC) was compared to usual care of slow deliberate up-titration. Most patients were on some form of treatment before the trial. In this paper, patients aged  $>65$  years were analysed. Mortality was not different between HIC and usual care, nor was the HF readmission rate. And fewer than 20% of patients were older than 75 years. HIC patients had quite an intense follow up as well. This is one of a number of studies that tries to encourage faster titration of HF medication, here even for the elderly. Reassuring to know, but I am not sure how it translates to my daily practise.

**Reference:** *Eur J Heart Fail* 2023; published online May 29

[Abstract](#)



### CONGRATULATIONS TO

Angela Taylor (Specialist Nurse at Nelson Hospital),  
Claire Aitken (Health Provider at Moana House) and  
Rohit Bedi (Dentist at Garden City Dental) who each were  
winners of a \$200 prezy card by taking part in our recent  
Research Review Annual Subscriber Update.

## Five-year follow-up after transcatheter repair of secondary mitral regurgitation

Authors: Stone GW et al., for the COAPT Investigators

**Summary:** This 5-year follow-up of the COAPT trial compared outcomes after TEER of severe mitral regurgitation compared with guideline-directed medical therapy (GDMT) in patients with HF. 614 patients with HF and moderate-to-severe or severe secondary mitral regurgitation who were symptomatic despite taking maximal doses of GDMT were randomised to undergo TEER plus receive GDMT (device group) or to receive GDMT alone (controls) at 78 sites in the US and Canada. The annualised rate of HF hospitalisations through 5 years was lower in the device group than the control group (33.1% vs 57.2% per year; HR 0.53, 95% CI 0.41–0.68). Five-year all-cause mortality was also lower in the device group (57.3% vs 67.2%; HR 0.72, 95% CI 0.58–0.89), as was 5-year death or hospitalisation for HF (73.6% vs 91.5%; HR 0.53, 95% CI 0.44–0.64). Device-specific safety events occurred in 1.4% of patients, with all events reported within 30 days after the procedure.

**Comment:** The COAPT trial was one of two trials published in 2018 on TEER – interventionally placing a clip on the commissures of the mitral valve to create a double orifice mitral valve, and reduce the mitral regurgitation. Specifically, patients with severe HF and functional mitral regurgitation were treated. The question for this paper was in particular the durability of the implant and hence this 5-year follow-up paper was highly anticipated. Controls were on GDMT. Mortality was reduced by 28%, hospitalisation for HF by 47%. The survival curves show that the benefits were initially achieved by the procedure and then persisted over time. Unlike other device trials, reintervention was uncommon (11/302). Overall, COAPT confirmed the benefit of TEER in a selective group of patients with functional mitral regurgitation, with the mortality number needed to treat between 5.9 and 7.9.

Reference: *N Engl J Med* 2023;388:2037-48

[Abstract](#)

## Family screening for bicuspid aortic valve and aortic dilatation

Authors: Bray JJH et al.

**Summary:** This meta-analysis investigated the prevalence of bicuspid aortic valve (BAV) and aortic dilatation in first-degree relatives of individuals with BAV. A search of MEDLINE, Embase, and Cochrane CENTRAL identified 23 observational studies involving 2297 index cases and 6054 screened relatives that were suitable for inclusion. Meta-analysis of the data showed that the prevalence of BAV in relatives was 7.3% overall, and 23.6% per family. The prevalence of aortic dilatation in relatives was 9.4% overall, and 29.2% in relatives with BAV. Aortic dilatation alongside tricuspid aortic valves was more common. The prevalence estimate in relatives with tricuspid valves (7.0%) was higher than that reported in the general population.

**Comment:** Should we do screening echos for family members of BAV patients? This paper tries to guide our decision by summarising data from 23 trials, including data from 2297 BAV patients and 6054 screened relatives. The prevalence of BAV in screened relatives was 7.3% – the key figure of this paper. It is assumed that this prevalence is more than 10-fold higher than that in the general population. In relatives with BAV, 29.2% also had aortic dilatation at the time of screening. The authors critically discuss the role of screening echos, but at least the data give us some evidence when speaking to patients and their families.

Reference: *Eur Heart J* 2023; published online Jun 8

[Abstract](#)

## Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF)

Authors: Brugs JJ et al., for the MONITOR-HF Investigators

**Summary:** The open-label MONITOR-HF trial investigated the utility of remote haemodynamic monitoring of pulmonary artery pressure in patients with chronic HF. At 25 centres in the Netherlands, 348 patients with chronic HF (mean age 69 years, mean LVEF 30%, New York Heart Association class III) and a previous HF hospitalisation were randomised 1:1 to remote haemodynamic monitoring (CardioMEMS-HF system) on top of usual care, or usual care alone. Patients in the monitoring group had a small, wireless, battery-free sensor implanted into the pulmonary artery via the femoral vein. A pressure measurement was taken each morning and readings were sent to a secure website. Physicians accessed the data and set a target pressure for each patient which would indicate the need to review drug treatment. The mean change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score at 12 months (primary end-point) was +7.05 in the CardioMEMS group ( $p=0.0014$ ) and  $-0.08$  in the standard care group ( $p=ns$ ). During a mean follow-up of 1.8 years there were 117 HF hospitalisations or urgent visits in the monitoring group and 212 in the usual care group, representing a 44% reduction with monitoring (HR 0.56, 95% CI 0.38–0.84;  $p<0.01$ ).

**Comment:** How do we monitor HF patients? In this trial, half the patients were randomised to an implanted device that measures pulmonary artery pressure. 348 with quite severe HF (mean LVEF 30%) and at least one previous admission for HF were included. The main outcome was change in KCCQ-measured quality of life; monitoring increased the chances of an improvement in measured quality of life (HR 1.56). However, I note that in the TriClip trial a KCCQ increase of 15 was seen as relevant while in this trial 5 was used as the cut-off. Overall, the trial illustrates a current trend in developing more implantable remote-monitoring devices. And also a trend in using quality of life as the predominant outcome parameter.

Reference: *Lancet* 2023;401(10394):P2113-23

[Abstract](#)

**Independent Content:** The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

**Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

**Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.

## Independent commentary by Professor Alexander Sasse

Professor Alexander Sasse is Consultant Cardiologist and Clinical Director of the Cardiology Department at Wellington Hospital/CCDHB. His clinical interests include the various modalities of cardiac imaging, structural heart disease and intervention, general cardiology and the prevention of stroke. He went to Medical School in Bonn and did his training at the RWTH Aachen (Germany) and has been a Cardiologist since 2004. In 2007 he moved to Wellington and has been there since. Appointments include being a senior lecturer at Wellington School of Medicine (University of Otago) since 2007, and adjunct Professor at the School of Biological Sciences (Victoria University) Wellington since 2012.



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#).



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).